High baseline serum thymidine kinase 1 level predict unfavorable outcome in patients with folicular lymphoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33117919" target="_blank" >RIV/61989592:15110/12:33117919 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.3109/10428194.2011.654339" target="_blank" >http://dx.doi.org/10.3109/10428194.2011.654339</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/10428194.2011.654339" target="_blank" >10.3109/10428194.2011.654339</a>

Jazyk výsledku

angličtina

Název v původním jazyce

High baseline serum thymidine kinase 1 level predict unfavorable outcome in patients with folicular lymphoma

Popis výsledku v původním jazyce

Abstract Serum thymidine kinase 1 (TK1) is a sensitive marker of tumor cell proliferation. TK1 was reported as a reliable prognostic factor in solid tumors and chronic lymphocytic leukemia, but has not been tested in large populations of non-Hodgkin lymphoma patients yet. In this study, a prognostic significance of TK1 levels was assessed in 170 prospectively enrolled patients with previously untreated follicular lymphoma. The TK1 level at the time of treatment initiation was shown to correlate with theclinical stage, FLIPI score, beta-2 microglobulin level, lactate-dehydrogenase level and B symptoms. No correlation was found with the FL grade or Ki-67 proliferative index. The Cox regression analysis identified high TK1 levels (?15 IU/L) as a prognostic factor for overall survival (hazard ratio 2.91, p=0.019) and progression-free survival (hazard ratio 1.94, p=0.022) independent of FLIPI score variables. Thus, TK1 levels may help refine risk assessment in the modern immunotherapy era.

Název v anglickém jazyce

High baseline serum thymidine kinase 1 level predict unfavorable outcome in patients with folicular lymphoma

Popis výsledku anglicky

Abstract Serum thymidine kinase 1 (TK1) is a sensitive marker of tumor cell proliferation. TK1 was reported as a reliable prognostic factor in solid tumors and chronic lymphocytic leukemia, but has not been tested in large populations of non-Hodgkin lymphoma patients yet. In this study, a prognostic significance of TK1 levels was assessed in 170 prospectively enrolled patients with previously untreated follicular lymphoma. The TK1 level at the time of treatment initiation was shown to correlate with theclinical stage, FLIPI score, beta-2 microglobulin level, lactate-dehydrogenase level and B symptoms. No correlation was found with the FL grade or Ki-67 proliferative index. The Cox regression analysis identified high TK1 levels (?15 IU/L) as a prognostic factor for overall survival (hazard ratio 2.91, p=0.019) and progression-free survival (hazard ratio 1.94, p=0.022) independent of FLIPI score variables. Thus, TK1 levels may help refine risk assessment in the modern immunotherapy era.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia & Lymphoma

ISSN

1042-8194

e-ISSN

—

Svazek periodika

53

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

1306-1310

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—